Effect of One-Year Subcutaneous and Sublingual Immunotherapy on Clinical and Laboratory Parameters in Children with Rhinitis and Asthma: A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy Study

Yükselen, Ayfer; Kendirli, Seval Güneşer; Yılmaz, Mustafa; Altıntaş, Derya Ufuk; Karakoç, Gülbin Bingöl

doi:10.1159/000327566

Cited by 159 publications

(149 citation statements)

References 81 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…Desiree et al [16] have assessed the findings from 31 studies on SCIT and concluded that the patients treated with D. pteronyssimus extract experienced 12-fold reduction in specific BHR after only 4-month of treatment compared with no change in the control group (p=0.002). Similar results were obtained in a study by Yukselen et al [17], which included 10 children treated with SCIT, 10 with SLIT and 10 children were on placebo during one year. The patients treated with SCIT showed significant increase in HDM (house dust mite) -specific bronchial provocation doses after 12 months.…”

Section: Discussionsupporting

confidence: 87%

“…Mean FEV1 values in their study showed an average increase by 6.3% in SCIT, 5.5% in SLIT and 0.7% in the placebo group. When compared with baseline values, FEV1 increased significantly in SCIT and SLIT, but did not change significantly in the placebo group [17].…”

Section: Discussionmentioning

confidence: 73%

“…Yekselen et al [17] have studied the effects of SCIT and SLIT in children with rhinitis and asthma during 12 months. The authors reported mean FEV1 values in the SCIT, SLIT and placebo group which were 99.2 ± 10.0, 97.8 ± 7.6 and 96.2 ± 10.2, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Frequency and Intensity of Bronchial Hyper-Reactivity in Patients with Allergic Asthma on Immunotherapy

Luljeta¹,

MehiÄ²,

Gojak³

et al. 2015

Immunome Res

View full text Add to dashboard Cite

Allergen immunotherapy significantly reduced asthma symptoms and medications requirements. Treated patients were significantly less likely to report symptomatic deterioration and less likely to require increased medication. This immunotherapy showed no consistent effect on lung function.The aim of study: In this study, we have determined the difference in the frequency and intensity of bronchial hyper-reactivity in patients with allergic asthma on immunotherapy compared to the patients with allergic asthma receiving only anti-asthmatic pharmacotherapy during one year period of time.Methods: 60 patients were included with allergic asthma, where genders were subsequently divided into two treatment groups. The study group included 30 patients who had received immunotherapy (immunotherapy group) and control group of 30 patients treated with standard pharmacotherapy, but not with immunotherapy (GINA proposal). Each patient in the immunotherapy group was treated with subcutaneous specific immunotherapy (SCIT). The criteria for the inclusion of the patients were clinical diagnosis of allergic asthma, age between 15 and 30 years, and both sexes. The criteria for the exclusion of the patients were the presence of other acute and chronic diseases of respiratory airways, other allergic diseases (skin allergies, nutritive allergies etc.), and acute and chronic diseases of other organic systems.Results: During the 1 st trimester, the median FEV1 values in control group of patients was 60.5% (46.7-78.25%) and following bronchodilators therapy, it was 81% (56-82.2%), which was a significant (p=0.005). In the immunotherapy group, median FEV1 value was 74% (66.0-77.0%) and following bronchodilator therapy it was 84% (76-89.5%), which was a significant increase (p=0.005). During the 2 nd trimester, the median FEV1 value in control group of patients was 75% (50-79.5%) and following bronchodilators therapy it increased up to 84% (66-88.5%) but the difference was not significantly different (p=0.08). In immunotherapy group, median FEV1 value was 78% (75.5-79.0%) and following bronchodilator therapy, it increased to 82% (79.5-83.75%) but the difference was not significant (p=0.066). During the 3rd trimester, the median FEV1 value in control group of patients was 70% (43-75%) and not significantly increased following bronchodilators therapy up to 84% (51-85%) (p=0.08). In experimental (immunotherapy) group, median FEV1 value was 77% (70-79%) and following bronchodilator therapy, it did not significantly change 76% (68-85%) (p=0.273). During the 4 th trimester, the median FEV1 value in control group of patients was 65% (54-75%) and significantly increased following bronchodilators therapy to 79% (55-83%) (p=0.018). In immunotherapy group, median FEV1 value was 79% (68-79.5%) and did not change significantly following bronchodilator therapy 90% (67.5-95.75%)) (p=0.18). Conclusion:In this study, the frequency of bronchial hyper reactivity was not significantly different in patients with allergic asthma treated with immunotherapy ...

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 73%

See 1 more Smart Citation

The Frequency and Intensity of Bronchial Hyper-Reactivity in Patients with Allergic Asthma on Immunotherapy

Luljeta¹,

MehiÄ²,

Gojak³

et al. 2015

Immunome Res

View full text Add to dashboard Cite

show abstract

“…Em estudos clínicos, além de servir como fator de identificação a sensibilizações, serve como avaliação da resposta a tratamentos para atopia, como, por exemplo, a imunoterapia [30] e em programas de educação em doenças alérgicas, fazendo com que o paciente visualize a resposta alérgica, reforçando a informação verbal e ajudando na avaliação da causa-efeito da alergia. Medidas de controle ambiental devem ser mantidas em conjunto com a prevenção da sensibilização alérgica e na redução de manifestações clínicas em pacientes com asma ou rinite alérgica [32].…”

Section: /10unclassified

Teste cutâneo em doenças alérgicas: uma revisão sistemática

Soldera

Bugança

Santos

et al. 2015

Sci Med

View full text Add to dashboard Cite

RESUMOObjetivos: Identificar os principais alérgenos aplicados em testes cutâneos para sensibilização atópica em pacientes com diagnóstico de asma e rinite alérgica. Métodos: Uma revisão sistemática foi realizada para identificar estudos clínicos nos últimos 10 anos, tendo como desfecho a utilização do teste cutâneo (prick test) no diagnóstico de asma e rinite alérgica. Foi realizada uma pesquisa nas bases de dados PubMed, Scielo e ScienceDirect. Foram incluídos artigos que abordam a utilização direta do teste cutâneo no diagnóstico das doenças alérgicas. Além disso, os estudos obrigatoriamente deveriam descrever o protocolo de utilização, bem como os alérgenos aplicados no teste. Para seleção dos artigos, três pesquisadores analisaram de forma independente os critérios de inclusão, sendo os mesmos analisados por mais dois revisores. Resultados: Treze instrumentos foram incluídos na sistemática, tendo uma variação expressiva na quantidade de reagentes (de 3 a 36 tipos). Dos 36, cinco possuíram a maior frequência de positividade à sensibilização (Artemisia vulgaris, Dermatophagoides farinae, Dermatophagoides pteronyssinus, epitélios de cão e de gato). Como parte do protocolo de aplicação, a região do antebraço e o período de 15 a 20 minutos são os mais frequentes. Conclusões: Alérgenos mais comuns em alergia respiratória foram descritos, sendo importante levar em consideração a região e população investigadas.DESCRITORES: testes cutâneos; diagnóstico; asma; rinite. ABSTRACT Aims:To identify the major allergens used in skin tests for atopic sensitization in patients with asthma and allergic rhinitis. Methods: A systematic review was performed to identify clinical studies in the past 10 years whose outcomes included the skin test (prick test) in the diagnosis of asthma and allergic rhinitis. The PubMed, SciELO, and ScienceDirect databases were searched and articles that addressed the direct use of skin testing in the diagnosis of allergic diseases were included. In addition, the studies had to describe the protocol and the allergens used in the test. For selection of the articles, three researchers independently analyzed the inclusion criteria, which were analyzed by two other reviewers. Results: Thirteen instruments were included in the systematic review, and the amount of reagents used varied significantly (between 3 and 36). Of the 36 reagents, five had the highest frequency of positive sensitization (Artemisia vulgaris, Dermatophagoides farinae, Dermatophagoides pteronyssinus, dog and cat epithelia). As part of the application protocol, the forearm and the period of 15-20 minutes are the most frequently used. Conclusions:The most frequently detected allergens were described, and both the region and the studied population are important factors to be considered.

show abstract

“…Alternative routes Sublingual -Sublingual administration of allergen-containing drops or tablets [17,24,[74][75][76][77][78][79] Oral -Oral administration of allergens (i.e. allergy vaccines that are swallowed) [68][69][70] Intralymphatic -Injection of allergy vaccines into the lymph node (instead of subcutaneous injection) [81][82][83] Epicutaneous -Epicutaneous administration of allergens using patch application [84][85][86][87] C. Virus-like particles…”

Section: Coupled Allergensmentioning

confidence: 99%

Allergen‐specific immunotherapy: from therapeutic vaccines to prophylactic approaches

Valenta

Campana

Marth

et al. 2012

Journal of Internal Medicine

101

View full text Add to dashboard Cite

Immunoglobulin E-mediated allergies affect more than 25% of the population. Allergen exposure induces a variety of symptoms in allergic patients, which include rhinitis, conjunctivitis, asthma, dermatitis, food allergy and life-threatening systemic anaphylaxis. At present, allergen-specific immunotherapy (SIT), which is based on the administration of the disease-causing allergens, is the only diseasemodifying treatment for allergy. Current therapeutic allergy vaccines are still prepared from relatively poorly defined allergen extracts. However, with the availability of the structures of the most common allergen molecules, it has become possible to produce well-defined recombinant and synthetic allergy vaccines that allow specific targeting of the mechanisms of allergic disease. Here we provide a summary of the development and mechanisms of SIT, and then review new forms of therapeutic vaccines that are based on recombinant and synthetic molecules. Finally, we discuss possible allergen-specific strategies for prevention of allergic disease.

show abstract

Effect of One-Year Subcutaneous and Sublingual Immunotherapy on Clinical and Laboratory Parameters in Children with Rhinitis and Asthma: A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy Study

Cited by 159 publications

References 81 publications

The Frequency and Intensity of Bronchial Hyper-Reactivity in Patients with Allergic Asthma on Immunotherapy

The Frequency and Intensity of Bronchial Hyper-Reactivity in Patients with Allergic Asthma on Immunotherapy

Teste cutâneo em doenças alérgicas: uma revisão sistemática

Allergen‐specific immunotherapy: from therapeutic vaccines to prophylactic approaches

Contact Info

Product

Resources

About